KRAS and lung cancer: Furthermore, clinical findings in patients with lung cancer given AMG510 and anti–PD-1/PD-L1 in combination (NCT03600883) indicate that KRAS G12C inhibition sensitizes the TME and enhances TIL infiltration into the tumor site, increasing the efficacy of immunotherapy.